SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Revolution Medicines held its annual stockholder meeting on June 18, 2026, with shareholders voting on the election of two Class III directors (Alexis Borisy and Mark A. Goldsmith, M.D., Ph.D.), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation.
View raw filing on EDGAR →Taysha announced completion of dosing in the REVEAL pivotal trial for TSHA-102 and reported positive longer-term clinical data from Part A, including 100% of patients gaining/regaining developmental milestones and 310 total functional gains at ≥12 months post-treatment, representing a material clinical and regulatory milestone advancing toward BLA submission in 1H 2027.
View raw filing on EDGAR →Virgin Galactic is issuing shares of common stock and pre-funded warrants in exchange for approximately $52.5 million in principal amount of convertible notes. This is an unregistered equity issuance relying on Section 4(a)(2) of the Securities Act, issued to qualified institutional buyers and accredited investors. The transaction is material as it reduces debt by 75% while diluting existing shareholders through the issuance of new equity securities, and the company explicitly states the purpose is to "improve liquidity, manage its cash position and strengthen its balance sheet" ahead of commercial operations.
View raw filing on EDGAR →The Board of Directors approved the separation and spin-off of Midera Food Processing, Inc. from Middleby Corporation into a new publicly traded company, with a pro rata distribution of Midera shares to Middleby stockholders scheduled for July 6, 2026. This constitutes a material change of control and disposition event—a significant restructuring that separates a major business unit and fundamentally alters the corporate structure. The filing explicitly references the Separation and Distribution Agreement and Form 10 registration statement, confirming this is a formal M&A-type transaction material to investors.
View raw filing on EDGAR →This Item 8.01 disclosure announces the completion of a material spin-off transaction—the separation of Middleby's Food Processing business into an independent, publicly traded company (Midera Food Processing, Inc.). The filing describes the distribution of 100% of SpinCo common stock to Middleby stockholders on a pro rata basis, with a distribution date of July 6, 2026, and Nasdaq listing under ticker "MFP." This constitutes a material change of control and restructuring of the registrant's ownership and capital structure, fitting the definition of ma_activity (change of control and separation transaction).
View raw filing on EDGAR →The disclosure centers on a new employment agreement with CEO Ramesh Srinivasan that establishes compensatory arrangements: a $600,000 base salary, annual bonus eligibility up to 150% of base salary, and a substantial $6.8 million RSU grant (78,269 units) with both time-based and performance-based vesting conditions tied to stock price targets ($105–$135 per share). The agreement also specifies severance and change-of-control provisions. This is a material executive compensation arrangement under Item 5.02(e).
View raw filing on EDGAR →This press release announces FDA accelerated approval of Tzield (teplizumab-mzwv) for a new indication—delaying decline in endogenous insulin production in children aged 8–17 with recently diagnosed stage 3 type 1 diabetes. The approval is a significant regulatory and commercial milestone for Sanofi's pipeline, expanding the drug's approved indications and market opportunity. While not a discrete M&A, debt, or capital event, the regulatory approval of a first-in-class disease-modifying therapy for a new patient population is a material operational and strategic development that would affect a reasonable investor's assessment of the company's product portfolio and revenue prospects.
View raw filing on EDGAR →Laura Cockrill was appointed as Executive Vice President and Chief Financial Officer effective June 22, 2026, succeeding Axel André who will depart July 17, 2026. The appointment of a new CFO to this critical C-suite position is material to investors as it affects the company's financial leadership and governance structure.
View raw filing on EDGAR →Digital Realty announced three material acquisition transactions totaling approximately $1.61 billion: acquisition of approximately 1,440 acres of land in Kansas City for ~$475 million, increase in Teraco ownership from 61% to 77% through acquisition of a 16% stake for ~$650 million, and acquisition of Columbia Capital for ~$485 million. These transactions are funded principally through issuance of 6.3 million shares of common stock and are expected to enhance the company's growth profile.
View raw filing on EDGAR →Jaguar Health's Board has initiated a process to explore and review strategic alternatives "focused on maximizing stockholder value," explicitly including "mergers, reverse mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions." This disclosure of an active exploration process for potential M&A activity or change-of-control transactions is material to investors assessing the company's future direction and value, even though no specific transaction has been announced yet.
View raw filing on EDGAR →SOPHiA GENETICS completed a $57.5 million public offering of 12,104,900 ordinary shares at $4.75 per share, including 1,578,900 shares from full exercise of the underwriters' option. The offering was initially announced and priced at $50 million for 10,526,000 shares, with the underwriters' option fully exercised at closing.
View raw filing on EDGAR →Ennis, Inc. issued a press release on June 22, 2026 announcing financial results for the quarter ended May 31, 2026, disclosing revenues of $98.6 million (up 1.4% YoY), net earnings of $9.9 million, and diluted EPS of $0.39 (up from $0.38), with gross profit margin improving to 31.5% from 31.1%.
View raw filing on EDGAR →EQT Infrastructure Company LLC disclosed an unregistered sale of 6,381,666 equity shares across multiple classes for aggregate consideration of approximately $171.8 million as of June 1, 2026, exempt from Securities Act registration under Section 4(a)(2), Regulation D, and/or Regulation S. Since inception on February 1, 2026, the Company has sold approximately $711.5 million of such shares as part of a continuous private offering, representing a material capital raise affecting investor assessment of ownership dilution and capital structure.
View raw filing on EDGAR →EQT Private Equity Company LLC completed an unregistered sale of approximately $41.9 million in equity shares (1,449,986 shares across multiple classes) to third-party investors as of June 1, 2026, under Section 4(a)(2) and Regulations D and S. This private placement is part of a continuous offering that has raised approximately $788.3 million since inception.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting held on June 18, 2026, covering three matters: election of 11 directors, advisory vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor. The filing directly corresponds to Item 5.07 and presents the vote tallies for each proposal, making this a textbook shareholder_vote_results event that is material to investors assessing corporate governance and board composition.
View raw filing on EDGAR →First Tracks entered into a 12-month sublease for approximately 45,057 square feet of office space in San Diego on June 15, 2026. While disclosed under Item 1.01 (Material Definitive Agreement), this is a real estate lease arrangement rather than an acquisition, disposition, merger, or change of control. The sublease is material to investors as it represents a significant operational commitment (45,000+ sq ft facility) and ongoing financial obligation, but it is fundamentally an operational/strategic business arrangement rather than a transaction fitting the M&A taxonomy. Classified as operational_other because the event is clearly operational (facility lease) but does not fit the specific M&A categories that Item 1.01 typically covers.
View raw filing on EDGAR →Spero Therapeutics announced FDA approval of Utebzi (tebipenem pivoxil), the company's lead product candidate for complicated urinary tract infections and the first-and-only oral carbapenem antibiotic approved in this indication. This represents a major regulatory milestone and transition from development to commercialization, materially affecting the company's commercial prospects and future revenue potential.
View raw filing on EDGAR →PennantPark Private Income Fund issued 110,906 common shares for approximately $2.864 million in an unregistered private offering relying on Section 4(a)(2) and Regulation D exemptions, diluting existing shareholders' ownership.
View raw filing on EDGAR →Joseph H. Jordan was appointed Chief Executive Officer and director of Domino's Pizza, effective October 1, 2026, following a multi-year succession planning process. The appointment follows Russell J. Weiner's transition to Executive Chairman and David A. Brandon's retirement from the Board.
View raw filing on EDGAR →Oric Pharmaceuticals held its annual meeting of stockholders on June 18, 2026, with voting results on five proposals: election of Class III directors (Jacob M. Chacko and Mardi C. Dier), ratification of KPMG LLP as independent auditor, approval of the amended 2020 Equity Incentive Plan, advisory approval of named executive officer compensation, and advisory vote on frequency of future compensation votes. All proposals passed.
View raw filing on EDGAR →BridgeBio held its Annual Meeting of Stockholders on June 16, 2026, at which shareholders voted on the election of two Class I directors (Peter Lebowitz and Frank P. McCormick) and the ratification of Deloitte & Touche LLP as independent auditor, with detailed vote tallies disclosed.
View raw filing on EDGAR →Adaptive Biotechnologies issued $345 million in aggregate principal amount of 0% Convertible Senior Notes due 2031 on June 22, 2026, with conversion mechanics, redemption provisions, and specified use of proceeds including $156.9 million to repay the OrbiMed Purchase Agreement, $25.6 million for capped call costs, $25.0 million for share repurchases, and remainder for general corporate purposes.
View raw filing on EDGAR →Adaptive Biotechnologies issued $300 million of convertible senior notes in a private placement to qualified institutional buyers under Rule 144A, with up to 20,034,840 shares of common stock potentially issuable upon conversion, representing a dilutive unregistered equity issuance.
View raw filing on EDGAR →Dr. Ichiro Aoki, co-founder and President of indie Semiconductor, resigned from the Board and his President role effective June 29, 2026, transitioning to a limited technical advisor role. Thomas Schiller was concurrently appointed to the Board as part of the leadership transition.
View raw filing on EDGAR →Legend Biotech announced the pricing of a public offering of 7.7 million ADSs at $29.35 per share, generating approximately $226 million in gross proceeds. This is a material equity issuance that creates a direct financial obligation and dilutes existing shareholders. While technically an equity offering rather than debt, the taxonomy's `debt_issuance` category encompasses "creation of a new direct financial obligation" and is the closest fit for capital-raising activities that materially affect the registrant's financial structure and shareholder base.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the Company's 2026 Annual Meeting of Stockholders held on June 17, 2026. The filing reports voting outcomes for three proposals: election of Class III directors (Proposal 1), ratification of PricewaterhouseCoopers LLP as independent auditor (Proposal 2), and advisory approval of named executive officer compensation (Proposal 3), with detailed vote tallies for each. This is a standard Item 5.07 disclosure and is material as it reflects stockholder approval of governance and compensation matters.
View raw filing on EDGAR →Ridgepost Capital, Inc. completed its acquisition of Stellus Capital Management, LLC on June 22, 2026, for $125 million in cash, 11.2 million membership units, and 579,096 shares of Class A Common Stock, plus up to $60 million in earnout payments. The acquisition of a $4 billion AUM direct lending platform represents a significant strategic transaction for the registrant.
View raw filing on EDGAR →Ridgepost Capital drew $139 million on its revolving credit facility and increased aggregate revolving commitments by $20 million under its Credit Agreement, with the proceeds used to fund the Stellus Capital Management acquisition.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from PepGen's 2026 Annual Meeting held on June 18, 2026. The filing reports voting outcomes for two proposals: election of three Class I directors (Mayer, Resnick, and Wyman) and ratification of KPMG LLP as independent auditor, with detailed vote tallies for each. This is a textbook Item 5.07 disclosure and is material to investors as it reflects stockholder approval of board composition and auditor selection.
View raw filing on EDGAR →Blue Owl Technology Finance Corp. entered into a Fourth Amendment to its Senior Secured Credit Agreement, extending the revolver maturity to June 2030 and scheduled maturity to June 2031, increasing the accordion provision to $4.01 billion, and adjusting sublimits and covenants. This amendment materially alters the Company's direct financial obligations and capital structure.
View raw filing on EDGAR →Public Storage announced entry into a definitive agreement to acquire Public Storage Canada for approximately $1.2 billion USD, consisting of $889 million in OP units, $310 million in cash, and potential earn-out consideration of up to $288 million. The acquisition includes 68 properties representing 5.3 million square feet and marks a strategic entry into the Canadian self-storage market.
View raw filing on EDGAR →Kendall Forbes, Executive Vice President of Sales & Operations since the company's founding in 2004, is retiring effective July 1, 2026, after 22 years of service.
View raw filing on EDGAR →David Morris is appointed Chief Operating Officer (promoted from CFO) and Will Mudd is appointed Chief Financial Officer (promoted from Senior Vice President, Finance), both effective July 1, 2026, as part of the company's executive leadership succession planning.
View raw filing on EDGAR →This 8-K Item 5.07 discloses the final voting results from American Well's 2026 annual stockholder meeting held on June 16, 2026, covering three proposals: election of directors (Dr. Ido Schoenberg), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory vote on named executive officer compensation. The filing presents the vote tallies (For, Withheld, Broker Non-Votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder vote results.
View raw filing on EDGAR →Seadrill announced an extension of its $500 million share repurchase program through December 31, 2026, with approximately $208 million remaining available as of June 19, 2026.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Equity Residential's June 18, 2026 Annual Meeting of Shareholders under Item 5.07. The filing reports final voting tallies for three proposals: election of ten trustees, ratification of Ernst & Young LLP as independent auditor, and advisory approval of executive compensation. All three proposals passed with substantial majorities, making this a routine but material governance disclosure required by Item 5.07.
View raw filing on EDGAR →CytomX held its Annual Meeting on June 17, 2026, with stockholders voting on seven proposals including election of Class II directors (Matthew P. Young and Elaine V. Jones Ph.D.), ratification of Ernst & Young LLP as auditor, authorization of additional common shares, amendments to the 2015 Equity Incentive Plan and Employee Stock Purchase Plan, advisory approval of named executive officer compensation, and the frequency of future advisory compensation votes.
View raw filing on EDGAR →Stockholders approved amendments to the Company's 2015 Equity Incentive Plan (increasing authorized shares by 6.5 million) and the Employee Stock Purchase Plan (increasing authorized shares by 1 million), expanding the pool of shares available for equity compensation and employee stock purchase eligibility.
View raw filing on EDGAR →This Item 5.07 disclosure reports the final voting results from Atea Pharmaceuticals' June 18, 2026 Annual Meeting of Stockholders, including the election of three Class III directors (Jerome Adams, Howard Berman, and Barbara Duncan), ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents certified vote tallies for each proposal and confirms their passage, which is the core purpose of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →Apollo Debt Solutions BDC sold 2,378,661 unregistered Class I Common Shares for $56.8 million to feeder vehicles, relying on Section 4(a)(2) and Regulation S exemptions from Securities Act registration.
View raw filing on EDGAR →Apollo Debt Solutions BDC declared distributions for each class of common shares on June 22, 2026, with per-share amounts of $0.1800 gross (varying net amounts after fees), payable to shareholders of record as of June 30, 2026, and to be paid on or around July 29, 2026, in cash or through the Fund's distribution reinvestment plan.
View raw filing on EDGAR →Eledon Pharmaceuticals held its Annual Meeting of Stockholders on June 22, 2026, at which shareholders voted on and approved three proposals: election of Class III Directors (Gros, Hillson, Robinson), approval of an amendment to increase authorized common shares from 300 million to 450 million, and ratification of Deloitte & Touche LLP as independent auditor.
View raw filing on EDGAR →This Item 7.01 disclosure is a shareholder letter from Apollo Debt Solutions BDC reporting quarterly performance metrics (net total return of +1.4% for the quarter, 1.5% year-to-date), investor flows ($0.3B gross inflows in Q2, $1.0B year-to-date), redemption activity (16.8% redemption requests, 5% honored), portfolio composition and credit quality metrics, and strategic positioning in the direct lending market. While it contains performance data, the disclosure is primarily operational and strategic in nature—discussing market conditions, capital deployment, portfolio health, and competitive positioning—rather than constituting a formal earnings release or financial results announcement. The material information about net outflows (~$0.4B, 3% of NAV) and redemption trends would affect investor assessment of the fund's capital flows and stability.
View raw filing on EDGAR →nCino held its Annual Meeting of Stockholders on June 18, 2026, with shareholders voting on and approving four proposals: election of directors (Jon Doyle, William Spruill, Diego Dugatkin, and Andy Yasutake), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of a charter amendment permitting stockholder removal of directors with or without cause.
View raw filing on EDGAR →The disclosure centers on the separation of Randall L. Baker, Chief Operating Officer, effective June 16, 2026. While the filing mentions severance benefits under the Executive Severance Plan, the principal disclosed action is the departure of a named executive officer from his role, making this an exec_departure event. The COO position is material to a reasonable investor's assessment of the company's leadership and operations.
View raw filing on EDGAR →Fortress Private Lending Fund entered into Amendment No. 3 to its Scotiabank ABL Credit Agreement, increasing the maximum aggregate commitments from $600 million to $950 million—a $350 million expansion of the credit facility with adjusted pricing terms.
View raw filing on EDGAR →On June 22, 2026, JHCPIF entered into an Agreement and Plan of Merger with MPCF and related parties, whereby Merger Sub will merge with MPCF, and the surviving entity will then merge into JHCPIF. This is a material acquisition/merger transaction requiring shareholder approval, with closing anticipated in Q3 2026. The exchange ratio is based on NAV calculations, and the transaction is structured as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.
View raw filing on EDGAR →On June 22, 2026, Manulife Private Credit Fund entered into an Agreement and Plan of Merger with John Hancock Comvest Private Income Fund, providing for a two-step merger in which MPCF will merge into JHCPIF. This is a material acquisition/change of control transaction requiring shareholder approval and SEC registration, with closing anticipated in Q3 2026. The merger consideration is based on an exchange ratio tied to the net asset values of both funds as of the determination date.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the Annual Meeting of Stockholders held on June 22, 2026. The filing presents tabulated voting results for two proposals: (1) election of eight directors and (2) ratification of BDO USA, P.C. as independent auditor. Item 5.07 is the designated 8-K item for shareholder vote results, and the prose explicitly states vote counts for each director and proposal, making this a material governance event affecting investor understanding of board composition and auditor selection.
View raw filing on EDGAR →This Item 5.07 discloses the final results of a Special Meeting of Stockholders held on June 18, 2026, where stockholders voted on two proposals to approve issuances of common stock pursuant to Nasdaq Rule 5635 — specifically approving up to 925,927 shares from Series A and B Warrants (Proposal 1) and 2,344,828 shares from Common Warrants (Proposal 2). Both proposals passed with overwhelming majorities. The disclosure of shareholder vote results at a stockholder meeting is the core purpose of Item 5.07, and approval of dilutive warrant exercises is material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →